Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.

A wide range of evidence shows that cholinesterase (ChE) inhibitors can interfere with the progression of Alzheimer's disease (AD). The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. However, clinical studies show that physostigmine has poor oral activity, brain penetration and pharmacokinetic parameters, while tacrine has hepatotoxic liability. Studies were then focused on finding a new type of acetylcholinesterase (AChE) inhibitor that would overcome the disadvantages of these two compounds. During the study, by chance we found a seed compound. We then conducted a structure-activity relationship study of this compound. After four years of exploratory research, we found donepezil hydrochloride (donepezil). Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil is currently marketed in 56 countries all over the world.

[1]  J. Morris,et al.  Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .

[2]  H. Ogura,et al.  Central and peripheral activity of cholinesterase inhibitors as revealed by yawning and fasciculation in rats. , 2001, European journal of pharmacology.

[3]  H. Ogura,et al.  Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. , 2000, Methods and findings in experimental and clinical pharmacology.

[4]  A. R. Green,et al.  Comparison of donepezil-, tacrine-, rivastigmine-and metrifonateinduced central and peripheral cholinergically mediated responses in the rat , 2000, Journal of psychopharmacology.

[5]  Y. Kuriya,et al.  Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. , 2000, European journal of pharmacology.

[6]  H. Ogura,et al.  Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. , 2000, Methods and findings in experimental and clinical pharmacology.

[7]  Y. Kuriya,et al.  Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. , 1999, European journal of pharmacology.

[8]  Y. Kuriya,et al.  Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. , 1999, European journal of pharmacology.

[9]  R. Doody.  Clinical benefits of a new piperidine-class AChE inhibitor , 1999, European Neuropsychopharmacology.

[10]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[11]  J. Pratt,et al.  Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020 , 1998, Psychopharmacology.

[12]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[13]  S. Tye,et al.  Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys , 1997, Psychopharmacology.

[14]  Y. Mimori,et al.  Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor , 1997, Behavioural Brain Research.

[15]  X. Tang,et al.  Huperzine A, a novel promising acetylcholinesterase inhibitor , 1996, Neuroreport.

[16]  D. Braida,et al.  An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. , 1996, European journal of pharmacology.

[17]  E. Giacobini,et al.  The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex , 1996, Neuropharmacology.

[18]  H. Sugimoto,et al.  Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. , 1995, Journal of medicinal chemistry.

[19]  T. Sato,et al.  Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). , 1995, Biological & pharmaceutical bulletin.

[20]  D. Knopman,et al.  The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.

[21]  K. Kawashima,et al.  Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  J. Blake,et al.  Novel benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase. , 1994, Journal of medicinal chemistry.

[23]  A. Galli,et al.  Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020. , 1994, European journal of pharmacology.

[24]  G. Dawson,et al.  The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory , 1993, Behavioural Brain Research.

[25]  A. Ohnishi,et al.  Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. , 1993, International journal of clinical pharmacology, therapy, and toxicology.

[26]  H. Sugimoto,et al.  Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives. , 1992, Journal of medicinal chemistry.

[27]  Martin R. Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[28]  C. J. Moore,et al.  The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties , 1992 .

[29]  T Nakamura,et al.  Novel piperidine derivatives. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. , 1990, Journal of medicinal chemistry.

[30]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[31]  B. Davies,et al.  HEPATOTOXICITY OF TETRAHYDROACRIDINE , 1988, The Lancet.

[32]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[33]  N. Sharpless,et al.  PLASMA PHYSOSTIGMINE CONCENTRATIONS AFTER ORAL ADMINISTRATION , 1985, The Lancet.

[34]  R. Whelpton,et al.  PHYSOSTIGMINE CONCENTRATIONS AFTER ORAL DOSES , 1985, The Lancet.

[35]  B. Reisberg,et al.  Effects of naloxone in senile dementia: a double-blind trial. , 1983, The New England journal of medicine.

[36]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[37]  A. Wettstein,et al.  No effect from double‐blind trial of physostigmine and lecithin in Alzheimer disease , 1983, Annals of neurology.

[38]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[39]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[40]  G. Marsh,et al.  Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. , 1981, Biological psychiatry.

[41]  J. Ferguson,et al.  Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia , 1981, British Journal of Psychiatry.

[42]  M. Sugishita,et al.  Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. , 1979, Archives of neurology.

[43]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[44]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[45]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[46]  D M Bowen,et al.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. , 1976, Brain : a journal of neurology.

[47]  Conn Nk,et al.  Letter: Avirulent corynebacteria. , 1975 .

[48]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[49]  Shaw Fh,et al.  The pharmacology of some new anti-cholinesterases. , 1953 .

[50]  K. Partanen.  MRI of Hippocampus in Incipient Alzheimer ' s Disease , 2003 .

[51]  Y. Kuriya,et al.  Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. , 1999, Japanese journal of pharmacology.

[52]  J. Morris,et al.  Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .

[53]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[54]  H. Ogura,et al.  Inhibitory Action of E2020, a Novel Acetylcholinesterase Inhibitor, on Cholinesterase: Comparison with Other Inhibitors , 1990 .

[55]  B. Davies,et al.  Hepatotoxicity of tetrahydroaminoacridine. , 1988, Lancet.

[56]  K. Davis,et al.  Oral physostigmine treatment of patients with Alzheimer's disease. , 1985, The American journal of psychiatry.

[57]  Memory enhancement with oral physostigmine in Alzheimer's disease. , 1983, The New England journal of medicine.

[58]  J. Massoulie,et al.  The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. , 1982, Annual review of neuroscience.

[59]  Ann Silver,et al.  The biology of cholinesterases , 1974 .

[60]  F. Shaw,et al.  The pharmacology of some new anti-cholinesterases. , 1953, The Australian journal of experimental biology and medical science.

[61]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .